# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment o...
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $14...
RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from...
A sentiment of risk aversion looms over the markets during Wednesday’s trading session, triggering midday losses across the boa...